InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.
From platelet concentrates that are not used in transfusion and are therefore condemned to destruction, Invenis Biotherapies applies its patented process to obtain a platelet lysate that is safer, more effective and compatible with the central nervous system (CNS).
The platelet lysate will be delivered directly to the site of interest, so directly into the CNS for ALS
The results of our research are extremely interesting with an effect on survival clearly superior to current treatments or the use of recombinant growth factors.
CEO & Co-founder
Doctor-Engineer in Biology
Serial entrepreneur in life science, he previously co-created InBrain Pharma and Colmeris Medtech Previously, project manager in biology/health at SATT Nord (Lille), his mission was to detect and manage innovative projects.
In 5 years, he detected more than 55 technologies, evaluated and set up 10 projects, obtained and managed more than 2 million euros of budget.
Professor in Neurology, University of Lille, Inserm, CHU of Lille.
She counts 81 articles, participated in 17 clinical trials which included 10 multicentre studies including one European and 3 as coordinator.
Assistant secretary of the SFN since 2016.
French representative's at the EAN.
Blood product specialist & Co-founder
Vice Dean, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
He has over 30 years of research and industrial experience in the manufacture of therapeutic human blood products and currently leads a research laboratory on new therapeutic applications of platelets in Taiwan.
He serves as an Expert on blood product quality issues for several international organizations and societies.
He has published more than 280 articles in international journals. He is also the inventor of 24 families of international patents relating to the manufacturing and viral inactivation processes of therapeutic blood products.
Professor of medical pharmacology, Neurologist at the university Lille, Inserm, University Hospital Center of Lille
His main domain of research concerns development of innovative therapeutic strategies in neurodegenerative diseases from the concept through in vitro and in vivo research to large phase clinical trials.
He participated in over 345 publications including 209 papers, conducted 30 clinical studies including 15 multi-centre trials, 14 as coordinator, 4 European Commission funded projects (H2020); career competitive research funding > 13M€
He is consultant and running research at the expert center of Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS) of Lille. He is co-coordinating the French network of PD (NS-Park-F-CRIN) and of ALS (ACT4ALS-MND) and is involved for the research in Lille national referent Expert centers for PD and ALS with large cohorts of patients. He is coordinating the neurogenetic center of Lille .
He obtained several awards: the European Pharmacology Prize, the French Medical Pharmacology Prize, the Health Professionals Competition prize Eurasanté University Foundation, I-SITE-ULNE, …